![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: PPARGC1B |
Gene summary for PPARGC1B |
![]() |
Gene information | Species | Human | Gene symbol | PPARGC1B | Gene ID | 133522 |
Gene name | PPARG coactivator 1 beta | |
Gene Alias | ERRL1 | |
Cytomap | 5q32 | |
Gene Type | protein-coding | GO ID | GO:0000302 | UniProtAcc | B7ZM40 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
133522 | PPARGC1B | A001-C-108 | Human | Colorectum | FAP | 1.46e-34 | -7.74e-01 | -0.0272 |
133522 | PPARGC1B | A002-C-021 | Human | Colorectum | FAP | 2.59e-08 | -3.71e-01 | 0.1171 |
133522 | PPARGC1B | A002-C-205 | Human | Colorectum | FAP | 1.45e-32 | -7.81e-01 | -0.1236 |
133522 | PPARGC1B | A001-C-104 | Human | Colorectum | FAP | 8.84e-19 | -6.42e-01 | 0.0184 |
133522 | PPARGC1B | A015-C-005 | Human | Colorectum | FAP | 8.61e-10 | -5.12e-01 | -0.0336 |
133522 | PPARGC1B | A015-C-006 | Human | Colorectum | FAP | 3.17e-21 | -7.86e-01 | -0.0994 |
133522 | PPARGC1B | A015-C-106 | Human | Colorectum | FAP | 2.67e-21 | -6.30e-01 | -0.0511 |
133522 | PPARGC1B | A002-C-114 | Human | Colorectum | FAP | 6.60e-22 | -6.31e-01 | -0.1561 |
133522 | PPARGC1B | A015-C-104 | Human | Colorectum | FAP | 6.94e-37 | -6.70e-01 | -0.1899 |
133522 | PPARGC1B | A001-C-014 | Human | Colorectum | FAP | 1.94e-32 | -7.50e-01 | 0.0135 |
133522 | PPARGC1B | A002-C-016 | Human | Colorectum | FAP | 2.67e-35 | -7.03e-01 | 0.0521 |
133522 | PPARGC1B | A015-C-002 | Human | Colorectum | FAP | 1.45e-18 | -7.88e-01 | -0.0763 |
133522 | PPARGC1B | A001-C-007 | Human | Colorectum | CRC | 7.34e-10 | -7.12e-01 | 0.1899 |
133522 | PPARGC1B | A001-C-203 | Human | Colorectum | FAP | 2.62e-17 | -6.02e-01 | -0.0481 |
133522 | PPARGC1B | A002-C-116 | Human | Colorectum | FAP | 9.30e-40 | -7.56e-01 | -0.0452 |
133522 | PPARGC1B | A014-C-008 | Human | Colorectum | FAP | 1.42e-16 | -5.78e-01 | -0.191 |
133522 | PPARGC1B | A018-E-020 | Human | Colorectum | FAP | 1.81e-25 | -6.78e-01 | -0.2034 |
133522 | PPARGC1B | F034 | Human | Colorectum | FAP | 1.35e-22 | -5.45e-01 | -0.0665 |
133522 | PPARGC1B | F072B | Human | Colorectum | FAP | 4.56e-29 | -7.46e-01 | 0.257 |
133522 | PPARGC1B | CRC-1-8810 | Human | Colorectum | CRC | 1.46e-37 | -8.83e-01 | 0.6257 |
Page: 1 2 3 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000701510 | Cervix | CC | actin filament organization | 109/2311 | 442/18723 | 4.92e-13 | 2.45e-10 | 109 |
GO:000697910 | Cervix | CC | response to oxidative stress | 102/2311 | 446/18723 | 2.99e-10 | 4.36e-08 | 102 |
GO:000030210 | Cervix | CC | response to reactive oxygen species | 56/2311 | 222/18723 | 1.00e-07 | 5.25e-06 | 56 |
GO:006219710 | Cervix | CC | cellular response to chemical stress | 76/2311 | 337/18723 | 1.01e-07 | 5.25e-06 | 76 |
GO:003009910 | Cervix | CC | myeloid cell differentiation | 83/2311 | 381/18723 | 1.31e-07 | 6.42e-06 | 83 |
GO:190370610 | Cervix | CC | regulation of hemopoiesis | 80/2311 | 367/18723 | 2.14e-07 | 9.55e-06 | 80 |
GO:004854510 | Cervix | CC | response to steroid hormone | 74/2311 | 339/18723 | 5.71e-07 | 2.09e-05 | 74 |
GO:00305229 | Cervix | CC | intracellular receptor signaling pathway | 60/2311 | 265/18723 | 1.89e-06 | 5.97e-05 | 60 |
GO:003459910 | Cervix | CC | cellular response to oxidative stress | 63/2311 | 288/18723 | 3.58e-06 | 9.50e-05 | 63 |
GO:00510904 | Cervix | CC | regulation of DNA-binding transcription factor activity | 87/2311 | 440/18723 | 4.85e-06 | 1.22e-04 | 87 |
GO:19021056 | Cervix | CC | regulation of leukocyte differentiation | 61/2311 | 279/18723 | 5.16e-06 | 1.29e-04 | 61 |
GO:004563710 | Cervix | CC | regulation of myeloid cell differentiation | 48/2311 | 210/18723 | 1.49e-05 | 2.93e-04 | 48 |
GO:00018949 | Cervix | CC | tissue homeostasis | 57/2311 | 268/18723 | 2.43e-05 | 4.21e-04 | 57 |
GO:00025738 | Cervix | CC | myeloid leukocyte differentiation | 47/2311 | 208/18723 | 2.48e-05 | 4.27e-04 | 47 |
GO:00456397 | Cervix | CC | positive regulation of myeloid cell differentiation | 28/2311 | 103/18723 | 3.56e-05 | 5.70e-04 | 28 |
GO:00319609 | Cervix | CC | response to corticosteroid | 39/2311 | 167/18723 | 5.48e-05 | 8.06e-04 | 39 |
GO:00602498 | Cervix | CC | anatomical structure homeostasis | 63/2311 | 314/18723 | 6.03e-05 | 8.68e-04 | 63 |
GO:00513849 | Cervix | CC | response to glucocorticoid | 35/2311 | 148/18723 | 9.87e-05 | 1.27e-03 | 35 |
GO:003530310 | Cervix | CC | regulation of dephosphorylation | 31/2311 | 128/18723 | 1.52e-04 | 1.83e-03 | 31 |
GO:003461410 | Cervix | CC | cellular response to reactive oxygen species | 35/2311 | 155/18723 | 2.59e-04 | 2.85e-03 | 35 |
Page: 1 2 3 4 5 6 7 8 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa04931 | Colorectum | MSS | Insulin resistance | 36/1875 | 108/8465 | 4.74e-03 | 2.01e-02 | 1.23e-02 | 36 |
hsa049311 | Colorectum | MSS | Insulin resistance | 36/1875 | 108/8465 | 4.74e-03 | 2.01e-02 | 1.23e-02 | 36 |
hsa049312 | Colorectum | FAP | Insulin resistance | 32/1404 | 108/8465 | 4.90e-04 | 3.56e-03 | 2.16e-03 | 32 |
hsa049313 | Colorectum | FAP | Insulin resistance | 32/1404 | 108/8465 | 4.90e-04 | 3.56e-03 | 2.16e-03 | 32 |
hsa049314 | Colorectum | CRC | Insulin resistance | 28/1091 | 108/8465 | 1.78e-04 | 2.37e-03 | 1.61e-03 | 28 |
hsa049315 | Colorectum | CRC | Insulin resistance | 28/1091 | 108/8465 | 1.78e-04 | 2.37e-03 | 1.61e-03 | 28 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PPARGC1B | SNV | Missense_Mutation | novel | c.2272C>T | p.His758Tyr | p.H758Y | Q86YN6 | protein_coding | deleterious(0.01) | possibly_damaging(0.869) | TCGA-A2-A0EQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
PPARGC1B | SNV | Missense_Mutation | c.2455N>T | p.Asp819Tyr | p.D819Y | Q86YN6 | protein_coding | deleterious(0.01) | possibly_damaging(0.751) | TCGA-A8-A0A7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
PPARGC1B | SNV | Missense_Mutation | novel | c.2773N>A | p.Phe925Ile | p.F925I | Q86YN6 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-AN-A03X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PPARGC1B | SNV | Missense_Mutation | novel | c.398N>T | p.Ser133Phe | p.S133F | Q86YN6 | protein_coding | deleterious(0.05) | possibly_damaging(0.823) | TCGA-AR-A2LH-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD |
PPARGC1B | SNV | Missense_Mutation | novel | c.759N>G | p.Asp253Glu | p.D253E | Q86YN6 | protein_coding | tolerated(0.17) | probably_damaging(0.991) | TCGA-B6-A2IU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
PPARGC1B | SNV | Missense_Mutation | c.2384N>A | p.Ser795Asn | p.S795N | Q86YN6 | protein_coding | deleterious(0.01) | probably_damaging(0.995) | TCGA-BH-A0W5-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | CR | |
PPARGC1B | SNV | Missense_Mutation | c.200N>C | p.Asn67Thr | p.N67T | Q86YN6 | protein_coding | tolerated(0.22) | benign(0) | TCGA-BH-A18Q-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
PPARGC1B | SNV | Missense_Mutation | rs559196017 | c.431N>T | p.Ser144Leu | p.S144L | Q86YN6 | protein_coding | tolerated(0.53) | benign(0) | TCGA-E2-A152-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Targeted Molecular therapy | trastuzumab | PD |
PPARGC1B | insertion | Frame_Shift_Ins | novel | c.2273_2274insGGATGGAAGGTGGATT | p.His758GlnfsTer7 | p.H758Qfs*7 | Q86YN6 | protein_coding | TCGA-A2-A0EQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | ||
PPARGC1B | insertion | Frame_Shift_Ins | novel | c.2232_2233insTTTTCTTT | p.Ala745PhefsTer14 | p.A745Ffs*14 | Q86YN6 | protein_coding | TCGA-AO-A0JB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD |
Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |